You are here

China

Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry

Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry

Endpoints

Gilead Sciences

Flag link:

The Chinese pharmaceutical market keeps growing and offering opportunities to large industrial groups

The Chinese pharmaceutical market keeps growing and offering opportunities to large industrial groups

GoinPharma

Flag link:

Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D

Touting its manufacturing strengths, Tot Biopharm raises $102M mega-round to ramp up cancer R&D

Endpoints

Flag link:

China Approves Gilead's Genvoya for HIV-1 Infection

China Approves Gilead's Genvoya for HIV-1 Infection

CP Wire

Gilead Sciences

Flag link:

Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech

Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech

Fierce Biotech

Flag link:

Clover Initiates Ph I Study of Enbrel Biosimilar in China

Clover Initiates Ph I Study of Enbrel Biosimilar in China

CP Wire

Clover BioPharmaceuticals

Flag link:

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

Hong Kong could become biotech listing hub, says BeiGene boss as Chinese drug maker gears up for US$1 billion flotation

South China Morning Post

Flag link:

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

CP Wire

Flag link:

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

CP Wire

monoclonal antibodies

Flag link:

Chance for global vaccine makers? China’s latest vaccine scandal sparks fury and fear

Chance for global vaccine makers? China’s latest vaccine scandal sparks fury and fear

Fierce Pharma

Flag link:

Ascentage third round garners $150M for apoptosis cancer drugs

Ascentage third round garners $150M for apoptosis cancer drugs

Fierce Biotech

Flag link:

Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline

Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline

Endpoints

Vivek Ramaswamy

Flag link:

As U.S. trade war escalates, China rolls out red carpet for Indian drugmakers

As U.S. trade war escalates, China rolls out red carpet for Indian drugmakers

Fierce Pharma

drug importation

Flag link:

Dying to Survive, China Shows the Way on Drug Prices

Dying to Survive, China Shows the Way on Drug Prices

Bloomberg

Flag link:

J&J taps German Merck to market Invokana in China

J&J taps German Merck to market Invokana in China

Biopharma Dive

Flag link:

Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China’s upstart biotechs

Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China’s upstart biotechs

Endpoints

Flag link:

Trump tariffs place $836 million in duties on the medtech industry

Trump tariffs place $836 million in duties on the medtech industry

Medical Design and Outsourcing

Flag link:

China speeds cancer drug price cuts amid outcry over smuggled Indian generics

China speeds cancer drug price cuts amid outcry over smuggled Indian generics

Fierce Pharma

Flag link:

4 Things You Need to Know About China and Biotech Investing

4 Things You Need to Know About China and Biotech Investing

Motley Fool

Flag link:

Boehringer Ingelheim BioXcellence adds fill-finish line to China plant

Boehringer Ingelheim BioXcellence adds fill-finish line to China plant

Fierce Pharma

Boehringer Ingelheim

drug manufacturing

Flag link:

Pages